SCHEMBL1034516

SCHEMBL1034516

COc1ccc(Cl)cc1-c1ccnc(NC2CCCC2)n1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 1/20 0.60
▸ EIF2AK2 P19525 2/20 0.55
▸ MAPK8 P45983 3/20 0.54
▸ MAPK9 P45984 3/20 0.54
▸ MAPK10 P53779 3/20 0.54
▸ CDK1 P06493 5/20 0.52
▸ CCNB1 P14635 5/20 0.52
▸ CDK4 P11802 4/20 0.52
▸ CCNA2 P20248 3/20 0.52
▸ CCND1 P24385 3/20 0.52
▸ CDK2 P24941 3/20 0.52
▸ CCNA1 P78396 3/20 0.52
▸ IKBKB O14920 2/20 0.49
▸ BCL6 P41182 1/20 0.48
▸ CCNE1 P24864 1/20 0.48
▸ CCND3 P30281 1/20 0.48
▸ CDK6 Q00534 1/20 0.48
▸ CCNB2 O95067 2/20 0.47
▸ CCNB3 Q8WWL7 2/20 0.47
▸ AGER Q15109 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1032136 0.99 SMN1; SMN2 (0.62) SMN1; SMN2EIF2AK2MAPK8MAPK9MAPK10
SCHEMBL3620677 0.99 SMN1; SMN2 (0.62) SMN1; SMN2EIF2AK2MAPK8MAPK9MAPK10
SCHEMBL3654146 0.91 SMN1; SMN2 (0.53) SMN1; SMN2EIF2AK2MAPK8MAPK9MAPK10
SCHEMBL12955857 0.91 SMN1; SMN2 (0.53) SMN1; SMN2EIF2AK2MAPK8MAPK9MAPK10
SCHEMBL1033717 0.89 SMN1; SMN2 (0.48) SMN1; SMN2EIF2AK2MAPK8MAPK9MAPK10
SCHEMBL1032622 0.88 MAPK10 (0.49) SMN1; SMN2EIF2AK2MAPK8MAPK9MAPK10
SCHEMBL1031594 0.86 EIF2AK2 (0.59) SMN1; SMN2EIF2AK2MAPK8MAPK9MAPK10
SCHEMBL1031173 0.85 AGER (0.54) SMN1; SMN2EIF2AK2MAPK8MAPK9MAPK10
SCHEMBL1032761 0.85 IKBKB (0.49) SMN1; SMN2MAPK8MAPK9MAPK10CDK1
SCHEMBL1031273 0.83 HDAC8 (0.56) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2010151747-A1 PYRIMINE COMPOUNDS AND METHODS OF MAKING AND USING SAME CYSTIC FIBROSIS FOUNDATION THERAPEUTICS, INC. (US) 2010-12-29 — — WO claimed
WO-2011008931-A2 ARYLPYRIMIDINE COMPOUNDS AND COMBINATION THERAPY COMPRISING SAME FOR TREATING CYSTIC FIBROSIS & RELATED DISORDERS CYSTIC FIBROSIS FOUNDATION THERAPEUTICS, INC. (US) 2011-01-20 — — WO disclosed
WO-2010151747-A1 PYRIMINE COMPOUNDS AND METHODS OF MAKING AND USING SAME CYSTIC FIBROSIS FOUNDATION THERAPEUTICS, INC. (US) 2010-12-29 — — WO disclosed
Send feedback